I’m once again dubious about weight loss drugs

Reports Physician’s First Watch, about a study in the New England Journal of Medicine:

Sibutramine Increases Risk for MI and Stroke Among Patients with Heart Disease

The weight-loss drug sibutramine (Meridia) — up for review by FDA advisers on Sept. 15 — poses increased risk for cardiovascular events among adults with cardiovascular disease (CVD), according to a New England Journal of Medicine study.

Editorialists, however, take a stronger stance: “Given that sibutramine has minimal efficacy for weight loss, no apparent benefit for clinical outcomes, [and] a worrisome cardiovascular risk profile, … it is difficult to discern a credible rationale for keeping this medication on the market.”

Meridia = Sibutramine

Dr John Ellis MD

Board-certified anesthesiologist, with expertise in cardiovascular anesthesia and the implications of obesity and sleep apnea in anesthesia. See vascularanesthesia.com for professional information. Dr. Ellis has used the strategies in here to: (1) lose 120 lbs over 18 months, (2) stop all antihypertensive medicines, and (3) no longer need CPAP treatment for sleep apnea.

One Comment:

  1. http://nyti.ms/dzasvE
    FDA advisory panel rejects another weight loss drug.

Comments are closed